BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 83 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,295 | -63.2% | 27,393 | -3.1% | 0.00% | – |
| Q2 2023 | $188,191 | +30010.6% | 28,257 | -15.6% | 0.00% | -100.0% |
| Q1 2023 | $625 | -5.7% | 33,490 | +8.5% | 0.00% | 0.0% |
| Q4 2022 | $663 | -99.8% | 30,854 | +1.7% | 0.00% | 0.0% |
| Q3 2022 | $359,000 | -4.5% | 30,353 | +6.5% | 0.00% | 0.0% |
| Q2 2022 | $376,000 | -1.3% | 28,511 | +56.6% | 0.00% | – |
| Q1 2022 | $381,000 | +16.5% | 18,206 | +13.1% | 0.00% | – |
| Q4 2021 | $327,000 | -29.7% | 16,102 | +5.2% | 0.00% | -100.0% |
| Q3 2021 | $465,000 | +10.5% | 15,312 | +5.6% | 0.00% | 0.0% |
| Q2 2021 | $421,000 | -28.2% | 14,498 | +6.8% | 0.00% | 0.0% |
| Q1 2021 | $586,000 | -16.8% | 13,575 | -10.9% | 0.00% | 0.0% |
| Q4 2020 | $704,000 | +17.5% | 15,230 | +10.2% | 0.00% | 0.0% |
| Q3 2020 | $599,000 | -27.0% | 13,818 | -10.6% | 0.00% | 0.0% |
| Q2 2020 | $820,000 | – | 15,463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |